Pulmonary Hypertension Group III Workstream

This Workstream was founded in March 2021 and is a collaborative platform between industry, academic, regulatory, and patient representatives. Its aim is to strengthen our community’s understanding of PH due to lung diseases. Every month they hold scientific discussions, often from their focus lectures and journal club. 

The Workstream aims to improve the care and daily living of PH group III patients by: 

• evaluating evidence and epidemiology 
• defining different phenotypes and endophenotypes 
• delineating innovative clinical trial endpoints 
• identifying novel diagnostic, digital solutions, and treatment approaches 

Consensus statements published in Pulmonary Circulation 

• PH in the setting of interstitial lung disease: Approach to management and treatment, January 2024 
• Pathogenesis, clinical features, and phenotypes of PH associated with interstitial lung disease, March 2023 
• PH in interstitial lung disease: Clinical trial design and endpoints, December 2022 
• Clinical significance of PH in interstitial lung disease, July 2022 

Articles published by the Workstream

• Inhaled Treprostinil in PH associated with interstitial lung disease: hope on the horizon, Steven Nathan and Eric Shen, May 2022
• Tobacco Smoking as Risk for PH, Manuel Richter, February 2022
• PH in COPD an unmet clinical need, Dario Vizza, Lucilla Piccari and Oksana Shlobin, September 2021
• PH associated with chronic lung disease: a constellation of phenotypes, Lucilla Piccari, April 2021
• Will the INCREASE study leverage Group 3 PH awareness and interest? Steven Nathan, April 2021

Working groups have been established to publish four more articles this year, including ‘The Significance of PH in COPD.’ 

PVRI 2024 Congress presentations